Skip to main content
. 2020 Dec 8;16(11):1201–1216. doi: 10.1080/15592294.2020.1853402

Figure 6.

Figure 6.

DNMT1 and DNMT3B are associated with progression-free (PFS) and overall survival (OS) of ovarian cancer patients. (a) Examples of DNMT1, DNMT3A and DNMT3B IHC immunostaining in sections from the same recurrent HGSOC tumour (original magnification: 200X). (b) Box plots show medians and 25–75 quartiles of DNMT1, DNMT3A, and DNMT3B IHC scores in recurrent HGSOC tumours (n = 32, Sample/Patient Group 2) before patients received guadecitabine treatment (*P < 0.05). (c) Scatter plots and correlation coefficients of IHC scores between DNMT1 and DNMT3A, DNMT1 and DNMT3B, or DNMT3A and DNMT3B in recurrent HGSOC tumours (n = 32, Sample/Patient Group 2). (d–g) Kaplan-Meier plots of progression-free survival (PFS) (d–e) and overall survival (f–g) by IHC score level (low or high) of DNMT1, or DNMT3B in recurrent HGSOC tumours from patients included in C above, and subsequently treated with a combination of carboplatin and guadecitabine. HR, hazard ratio